Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > COLUMN
COLUMN
- It’s Moments Like These
June 27, 2014
- How to Hire a Medical Doctor Who Is a Business Person First
May 23, 2014
- Transforming from a Key Opinion Leader to a Key Account
April 25, 2014
- Emerging Immunotherapy of Cancer: 2
April 11, 2014
- Emerging Immunotherapy of Cancer: 1
April 10, 2014
- Sun Tzu and the Art of Interviewing
March 18, 2014
- 2014: Year of the (Trojan) Horse – CROs Are about to Take the Pharma Industry by Storm
February 21, 2014
- The Time Is Now for Medical Affairs
January 17, 2014
- Blue Ocean Recruiting
December 20, 2013
- Recruitment: Save Yourself from the Insanity of Diminished Returns
November 22, 2013
- Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 2
November 8, 2013
- Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 1
November 7, 2013
- A World of Opportunity for the Brave
November 1, 2013
- Does HR Have an Image Problem?
September 20, 2013
- Learn How to Give a Great Presentation and You May Break the “Gaijin Ceiling” to the Board Room at Headquarters
August 21, 2013
- Watch out for the Gorilla when Hiring Talent
July 19, 2013
- Great Leaders Are Happy to Eat Humble Pie and Give the Credit to Others
June 21, 2013
- Lessons Learned from the Firing Line of Interviewing in a Bi-lingual and Bi-cultural Environment
May 23, 2013
- An Insider’s Perspective on Hiring in Japan
April 26, 2013
- Pharmaceutical Companies in Japan Cross Cultural Boundaries to Retain and Hire the Best and the Brightest
March 18, 2013
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…